I used to cover Aclaris Therapeutics and its topical JAK inhibitor product for androgenetic alopecia fairly regularly. However, there have been few significant recent updates.
Today morning, Aclaris released a summary of its FY 2018 results. The most relevant part for us concerns the ATI-502 topical product for androgenetic alopecia. They also seem to name this product as AGA-201 and ATI-50002.
Per the latest news, Phase 2 open-label clinical trials for ATI-502 (a topical JAK1/3 inhibitor) involve 31 patients with androgenetic alopecia (AGA). Interim 6-month data are expected in the second quarter of 2019, while comprehensive 12-month data will be realized in the second half of 2019.
So by the end of this year, we should finally have at least some idea on whether JAK inhibitors can at least somewhat help patients with AGA (aka male pattern hair loss). The trials will measure both safety and efficacy.
We already know beyond a doubt that JAK inhibitors significantly help people with the less common alopecia areata (AA) and its various related forms (alopecia totalis and alopecia universalis).